A 71-year-old male with a life-threatening recurrence of hemolytic anemia, thrombocytopenia, and acute kidney injury after pembrolizumab therapy: a case report
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, their use has been restricted in patients with preexisting autoimmune diseases due to concerns about increased risk of immune-related adverse events (irAEs). Case presentation We present a case of...
Main Authors: | Xin Zhang, Bi-xia Gao, Cui-yan Guo, Tao Su |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-08-01
|
Series: | BMC Geriatrics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12877-023-04181-w |
Similar Items
-
Danazol in Refractory Autoimmune Hemolytic Anemia or Immune Thrombocytopenia: A Case Series Report and Literature Review
by: Hsu-En Huang, et al.
Published: (2022-11-01) -
Autoimmune Hemolytic Anemia
by: Şinasi Özsoylu
Published: (2012-08-01) -
Development of New Drugs for Autoimmune Hemolytic Anemia
by: Zhengrui Xiao, et al.
Published: (2022-05-01) -
A Rare Association of Mixed Autoimmune Hemolytic Anemia with Gastric Carcinoma
by: Anu Chinnadurai, et al.
Published: (2023-10-01) -
Laboratory and clinical characteristics of patients diagnosed with HELLP syndrome due to microangiopathic hemolytic anemia and/or thrombocytopenia
by: Ömer Ekinci, et al.
Published: (2020-08-01)